Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
Open Access
- 1 January 2019
- journal article
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 9 (4) , e2019116
Abstract
Autops Case Rep, vol.9, n4, e2019116, 2019Keywords
This publication has 23 references indexed in Scilit:
- Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCCJournal of the American Academy of Dermatology, 2015
- An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinomaJournal of the American Academy of Dermatology, 2014
- Update of the European guidelines for basal cell carcinoma managementEuropean Journal Of Dermatology, 2014
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- A systematic review of worldwide incidence of nonmelanoma skin cancerBritish Journal of Dermatology, 2012
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2009
- Basal cell carcinomas: attack of the hedgehogNature Reviews Cancer, 2008
- Interventions for basal cell carcinoma of the skinCochrane Database of Systematic Reviews, 2007
- Somatic mutations in thePTCH,SMOH,SUFUHandTP53genes in sporadic basal cell carcinomasBritish Journal of Dermatology, 2005
- Developmental Genes and Cancer: Role of Patched in Basal Cell Carcinoma of the SkinJNCI: Journal of the National Cancer Institute, 1997